Menu
Not yet recruiting NCT07198802

Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma

Observational Nasopharyngeal Carcinoma (NPC)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: No Intervention.
Who it may be relevant to
Registry conditions: Nasopharyngeal Carcinoma (NPC). Basic parameters: 15 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma Based on Tumor Immune Microenvironment

Overview

To analyze the spatiotemporal dynamic evolution of nasopharyngeal carcinoma before and after immunotherapy and during tumor progression, 2\~3 key cell subsets or node molecules were screened to predict the curative effect. Spatial metabolome and organoids were used to elucidate the mechanism of key factors leading to immunotherapy tolerance in NPC and identify new targets for intervention.

Interventions

  • Other No Intervention
    This project involves no therapeutic intervention for the subjects.

Primary outcome measures

  • Failure-free survival (FFS) [Time frame: 3-year]
Secondary outcome measures (1)
  • Overall survival (OS) [Time frame: 5-year]

Eligibility criteria

Inclusion Criteria Before the trial, the participants must meet all of the following requirements to be eligible for inclusion.

  • Clearly diagnosed with nasopharyngeal carcinoma by pathology;
  • Patients who have received combined radiotherapy, chemotherapy and immunotherapy in our hospital;
  • Patients diagnosed in our hospital from January 2025 to December 2028;
  • Have relatively complete clinical data;
  • Age between 15 and 75 years old;

Exclusion Criteria Before the trial, the participants who meet any of the following requirements cannot be included.

  • The final diagnosis of the participants is other diseases, including lymphoma, or oropharyngeal cancer, etc.;
  • The participants failed to obtain pathological and imaging data for various reasons;
  • Due to physical conditions, they did not undergo relevant examinations, refused to accept examinations, or interrupted treatment for other reasons, and were unable to complete clinical assessment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07198802 · WuhanUH 1149-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗